---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-063202"
form_type: "8-K"
ticker: "CLRB"
cik: "0001279704"
company_name: "Cellectar Biosciences, Inc."
filed_at: "2026-05-18T20:15:33+00:00"
generated_at: "2026-05-18T21:13:30.082228+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Cellectar director Loren not standing for reelection; Nantahala analyst Gu appointed to board

## Summary
- Dr. Stefan Loren will not stand for reelection at 2026 annual meeting; no disagreement with the company.
- Loren enters consulting agreement: $15,000/quarter for one year, plus 15,000 stock option grant.
- Andrew Gu appointed as Class III director on May 18, 2026, selected by Nantahala Capital Management.
- Gu is an analyst at Nantahala, focuses on biotech; he joins the Audit Committee.

## SEC filing metadata
- accession: 0001104659-26-063202
- form_type: 8-K
- ticker: CLRB
- cik: 0001279704
- company_name: Cellectar Biosciences, Inc.
- filed_at: 2026-05-18T20:15:33+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1279704/000110465926063202/0001104659-26-063202-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1279704/000110465926063202/tm2614924d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-063202
- JSON: https://secwatch.observer/filing/0001104659-26-063202.json
- Plain text: https://secwatch.observer/filing/0001104659-26-063202.txt

## Key facts
- Executive change
  Stefan D. Loren departed as Class III Director at Cellectar Biosciences, Inc..
  - Action: not standing for reelection
  - Role: Class III Director
  source text: On May 17, 2026, Stefan D. Loren, Ph.D. notified the board of directors (the “Board”) of Cellectar Biosciences, Inc. (the “Company”), that he does not intend to stand for reelection as a Class III director at the upcoming 2026 annual meeting of the stockholders of the Company (the “Annual Meeting”), at which time his current term as a director will expire.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1279704/000110465926063202/0001104659-26-063202-index.htm
- Executive change
  Andrew Gu was appointed as Class III Director at Cellectar Biosciences, Inc..
  - Action: appointed
  - Role: Class III Director
  source text: On May 18, 2026, the Board appointed Mr. Gu to serve as a member of the Board as a Class III director.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1279704/000110465926063202/0001104659-26-063202-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.